Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European Association of Urology Guidelines on Testicular Cancer: 2023 Update
Anna Patrikidou, Walter Cazzaniga, Daniel M. Berney, et al.
European Urology (2023) Vol. 84, Iss. 3, pp. 289-301
Closed Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential
Dengxiong Li, Jie Wang, Zhouting Tuo, et al.
Phytomedicine (2024) Vol. 127, pp. 155503-155503
Closed Access | Times Cited: 11
Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study
Niklas B. Lindahl, Jakob Lauritsen, Thomas Wagner, et al.
Acta Oncologica (2025) Vol. 64, pp. 191-199
Open Access | Times Cited: 1
Testicular Germ Cell Tumors
Nirmish Singla, Aditya Bagrodia, Ezra Baraban, et al.
JAMA (2025)
Closed Access | Times Cited: 1
Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report
Nils C. H. van Creij, Gerald Klinglmair, Leonhard Gruber, et al.
Therapeutic Advances in Urology (2025) Vol. 17
Open Access | Times Cited: 1
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office
Joost L. Boormans, Richard Sylvester, Lynn Anson‐Cartwright, et al.
European Urology Oncology (2023) Vol. 7, Iss. 3, pp. 537-543
Closed Access | Times Cited: 15
Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma
Felix Seelemeyer, David Pfister, Roberto Pappesch, et al.
European Urology Oncology (2023) Vol. 7, Iss. 3, pp. 319-322
Closed Access | Times Cited: 14
The prognostic impact of treatment centralization in patients with testicular germ cell tumors: analysis of hospital-based cancer registry data in Japan
Shuhei Suzuki, Yoshiyuki Nagumo, Shuya Kandori, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 3, pp. 318-324
Open Access | Times Cited: 5
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
Karim Fizazi, Gwénaël Le Teuff, Aude Fléchon, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 28, pp. 3270-3276
Closed Access | Times Cited: 5
Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness
Mehdi Kardoust Parizi, Vitaly Margulis, Aditya Bagrodia, et al.
Urologic Oncology Seminars and Original Investigations (2024) Vol. 42, Iss. 4, pp. 102-109
Open Access | Times Cited: 4
Overview of Novel Biomarkers for Management of Postchemotherapy Residual Masses in Testicular Cancer
Renjie Ding, Xiangdong Li, Zhuowei Liu
European Urology Focus (2024) Vol. 10, Iss. 3, pp. 380-382
Closed Access | Times Cited: 4
Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours
Klaus‐Peter Dieckmann, Francesca Grobelny, Armin Soave, et al.
European Urology Focus (2024) Vol. 10, Iss. 5, pp. 851-857
Closed Access | Times Cited: 4
Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: should regional therapy be considered the preferred treatment approach?
Rachel Glicksman, Di Maria Jiang, Philippe L. Bédard, et al.
International Journal of Radiation Oncology*Biology*Physics (2025)
Open Access
Clinical profile, treatment, and outcomes of testicular cancer in a resource-limited setting: a study from Sudan
Eltahir Ahmed Eltahir, Sami Mahjoub Taha Awad, Yassin Mohammed Osman, et al.
African Journal of Urology (2025) Vol. 31, Iss. 1
Open Access
Biochemical Hypogonadism in Aging Testicular Cancer Survivors: A Clinical Challenge
Sophie D. Fosså, Lars Johan Bjerner, Torgrim Tandstad, et al.
European Urology Open Science (2025) Vol. 72, pp. 10-16
Open Access
Hodentumor – welche Vorteile bringt der neue Tumormarker microRNA-371a-3p (M371-Test)
Klaus‐Peter Dieckmann, Gazanfer Belge
TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 01, pp. 40-49
Closed Access
Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey
Anna Patrikidou, Christoph Oing, Christos Markellos, et al.
European Urology Oncology (2025)
Closed Access
METASTATIC PURE SEMINOMAS WITH EARLY RELAPSE: PROGNOSTIC ROLES OF HIGH DOSE CHEMOTHERAPY AND SURGERY OF RESIDUAL DISEASE.
Lucile Duval, Benoît Allignet, Christine Chevreau, et al.
Clinical Genitourinary Cancer (2025), pp. 102310-102310
Closed Access
Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer at a National Referral Centre
Konstantinos Evmorfopoulos, Panagiotis J. Vlachostergios, Georgios Chasiotis, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 608-608
Open Access
Preoperative semen quality is superior to the quality shortly after orchiectomy in patients with testicular germ cell tumour – a retrospective study from two centres in Germany
Klaus‐Peter Dieckmann, Johanna Hochmuth‐Tisch, Andrea Salzbrunn, et al.
Basic and Clinical Andrology (2025) Vol. 35, Iss. 1
Open Access
Is primary retroperitoneal lymph node dissection the way forward for patients with testicular seminoma and limited retroperitoneal metastases?
Mithun Kailavasan, Nicholas Power, Benjamin B. Beech
Urologic Oncology Seminars and Original Investigations (2025)
Open Access
Primary testicular teratoma with cystic retroperitoneal metastases
Martin Šabík, Alice Hlobílková, Radek Lakomý, et al.
(2025)
Closed Access
Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors
Huan Lin, Xiaowen Lin, Peisheng Huang, et al.
Andrology (2025)
Open Access
Die Bildgebung von Hodentumoren - Diagnostik, Staging und Nachsorge
Luca Funk, Uwe Bieri, Daniel Hausmann, et al.
Radiologie up2date (2025) Vol. 25, Iss. 01, pp. 37-55
Closed Access
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ cell tumors
Richard S. Matulewicz, Fady Baky, Nicole Liso, et al.
Annals of Oncology (2025)
Closed Access
The role of surgical resection of the primary tumor in metastatic upper tract urothelial carcinoma: a systematic review and meta-analysis
Mehdi Kardoust Parizi, Nirmish Singla, Morgan Rouprêt, et al.
Current Opinion in Urology (2025)
Closed Access
Page 1 - Next Page

Scroll to top